However, the success of these therapies depends not only on scientific innovation but also on highly specialized logistics infrastructure. The success of ATMPs depends on more than just scientific breakthroughs, it requires a highly controlled, risk-mitigated supply chain that ensures product integrity from research through commercialization. In 2027, Europe’s ATMP logistics ecosystem is evolving at unprecedented speed. Pharmaceutical manufacturers, logistics providers, biotech companies, and regulators are collaborating to create resilient, compliant, and scalable supply chains capable of handling personalized medicines with ultra-sensitive transportation requirements.
The Rising Demand for ATMP Logistics in Europe
Europe has emerged as a major global hub for cell and gene therapy development, with a growing number of clinical trials and commercial ATMP approvals across countries such as Germany, France, the Netherlands, Belgium, and the United Kingdom. According to industry estimates, Europe’s cell and gene therapy third-party logistics market is projected to surpass $5 billion by 2030, driven by rapid commercialization and increasing demand for personalized therapies. Even small temperature fluctuations or shipping delays can affect the safety and effectiveness of the treatment. This creates enormous pressure on logistics providers to maintain:
Chain of identity
Chain of custody
Real-time temperature control
Cross-border coordination
Rapid turnaround times
Regulatory compliance
Concluding that, ATMP logistics in 2027 is no longer viewed as a support function. It has become a strategic pillar of the European biotech ecosystem.
Cryogenic Cold Chain Infrastructure is Expanding
One of the biggest developments in Europe’s ATMP supply chain is the rapid expansion of cryogenic cold chain infrastructure. Many cell and gene therapies require storage and transport at temperatures as low as -196°C using liquid nitrogen dry vapor shippers. Traditional pharmaceutical cold chains operating between 2°C and 8°C are insufficient for these therapies. Specialized logistics providers are therefore investing in advanced cryogenic storage hubs near manufacturing centers and treatment hospitals. Industry reports describe cryogenic shipping as one of the most complex logistics challenges ever faced by the healthcare industry due to the combination of ultra-low temperatures, strict delivery windows, and patient-specific products.
By 2027, Europe is expected to see:
Expanded ultra-cold storage facilities
Regional cryogenic distribution centers
Increased use of smart packaging
Automated temperature monitoring systems
Redundant backup infrastructure for risk mitigation
Countries like Germany and the Netherlands are emerging as critical logistics gateways due to their advanced transportation infrastructure and proximity to major biotech clusters.
Digital Supply Chain Visibility is Becoming Essential
Digitalization is reshaping ATMP logistics across Europe. Since these therapies are patient-specific and extremely high-value, real-time monitoring has become essential for ensuring product integrity and regulatory compliance.
Modern ATMP logistics platforms now integrate:
These technologies allow logistics providers to monitor each stage of the therapy journey, from patient cell collection and manufacturing to final delivery. Digital visibility has become essential as ATMP supply chains involve many stakeholders, including hospitals, manufacturing sites, courier partners, regulators, and treatment centers. According to industry experts, the growing use of cloud-based logistics platforms and real-time tracking solutions is expected to drive significant market growth through 2030. In 2027, European logistics companies are prioritizing “zero-failure” delivery models where predictive analytics can proactively identify risks such as customs delays, weather disruptions, or equipment failures before they impact patient treatments.
Europe is Moving Toward Decentralized Manufacturing
Another major shift reshaping ATMP logistics is the move from centralized manufacturing toward decentralized and regional production models. Historically, many cell and gene therapies were manufactured in a small number of highly specialized facilities, often requiring cross-border transportation of biological materials. This created long transit times and increased operational risks. To improve scalability and reduce transportation complexity, Europe is investing in decentralized manufacturing networks closer to treatment centers.
This trend offers several advantages:
European governments and healthcare organizations are supporting regional manufacturing ecosystems through public-private partnerships and infrastructure funding. As ATMP commercialization accelerates, decentralized manufacturing is expected to become a key strategy for improving therapy accessibility across Europe.
Regulatory Harmonization is Accelerating Growth
Regulatory complexity has historically been a major barrier to scaling ATMP logistics across Europe. Different countries often maintained varying requirements for transportation, labeling, customs clearance, and biological handling. In 2027, the European Medicines Agency and national authorities are working towards greater harmonization of ATMP regulations to simplify cross-border logistics operations.
Recent regulatory initiatives focus on:
Industry experts believe regulatory harmonization will significantly reduce operational friction and improve scalability for both manufacturers and logistics providers. At the same time, compliance expectations are becoming stricter. Logistics companies must demonstrate end-to-end traceability, validated packaging systems, and comprehensive contingency planning. As a result, specialized ATMP logistics providers are gaining a competitive advantage over traditional pharmaceutical transport companies.
Supply Chain Resilience is Now a Strategic Priority
Global geopolitical instability, tariffs, raw material shortages, and transportation disruptions have exposed vulnerabilities in pharmaceutical supply chains over recent years. For ATMPs, supply chain resilience is especially critical because therapies are often irreplaceable and tied to individual patients. Industry reports highlight growing concerns over trade instability, sourcing challenges, and transportation disruptions impacting advanced therapy supply chains.
In response, European companies are implementing resilience strategies such as:
The focus in 2027 is shifting from cost optimization toward continuity and patient protection.
The Future of ATMP Logistics in Europe
By 2027, Europe’s ATMP logistics industry is becoming one of the most technologically advanced healthcare supply chain sectors in the world. The combination of cryogenic transportation, AI-driven monitoring, decentralized manufacturing, and regulatory harmonization is enabling Europe to scale cell and gene therapy delivery more efficiently than ever before. As more therapies receive commercial approval, logistics providers will play an increasingly important role in ensuring timely patient access to life-saving treatments. The future of ATMP logistics will rely on ongoing investments in infrastructure, digital innovation, and stronger cross-border collaboration. Companies that provide reliable, compliant, and scalable logistics solutions are expected to play a key role in advancing the next generation of personalized medicine. For Europe, the race to scale cell and gene therapy supply chains is not just about operational efficiency, it is about building the foundation for the future of healthcare itself.
World BI Pharma Supply Chain and Logistics Innovation Programme 2027
It’s is a global platform bringing together pharmaceutical leaders, supply chain experts, and logistics innovators to discuss the future of pharma supply chains. Organized by World BI, the conference Pharma Supply Chain and Logistics Innovation Programme will focus on digital transformation, cold chain excellence, risk management, logistics optimization, scalable innovation and so many other important topics. The event aims to foster collaboration, share industry insights, and address evolving challenges in pharmaceutical supply chain operations. Attendees will explore strategies to enhance efficiency, resilience, patient safety, and end-to-end supply chain visibility across the healthcare ecosystem